"We are pleased to be working with the Biosciences and Biotechnology Division at LLNL to develop our broad-spectrum coronavirus vaccine candidate," said Kimbell Duncan, CEO of ConserV Bioscience Limited, the UK-based company specializing in late-stage vaccine development that is now partnering with LLNL researchers.
"We have identified regions within the proteins of the virus that are not susceptible to change and if effective, the vaccine promises to protect against a broad spectrum of current circulating coronavirus strains and future emergent ones," Duncan added in a joint message.
On the technical side, the collaboration will bring together ConserV's expertise in identifying antigens and LLNL's nanolipoprotein particle (NLP) delivery system, according to officials at the labs.
The vaccine construct consists of conserved immunoreactive regions from external and internal coronavirus proteins, from each virus genus, encoded in messenger RNA, or mRNA, officials said. "The mRNA construct will be formulated with LLNL's propriety nanolipoprotein particle vehicle prior to injection, allowing freeze drying of both components separately to avoid cold chain storage and transport issues."
The NLPs, which are water-soluble molecules that are 6 to 30 billionths of a meter in size and resemble HDL particles in humans, are a nanotechnology (also known as nanodiscs) that LLNL scientists have been using as a delivery platform for tularemia and chlamydia vaccines that are under development, according to the lab.
"We look forward to combining our nanolipoprotein particle technology with ConserV's mRNA construct encoding conserved viral epitopes. We hope to advance the vaccine candidate to human trials as quickly as possible," LLNL biologist Amy Rasley said in a statement.
"Our NLP technology is very versatile, so we anticipate that we can tune our platform formulation to produce safe and effective vaccine candidates," added fellow LLNL principal investigator Nicholas Fischer, who is also working on the project in Livermore alongside Wei He, Matthew Coleman and Sandra Peters.
Coronaviruses, which are a group of single-stranded RNA viruses, can cause respiratory tract infections and other mild-to-lethal symptoms in humans -- and the novel strain of coronavirus (SARS-CoV-2) first identified in Wuhan, China in December 2019 has killed more than 2 million people worldwide and infected some 86-million-plus more during the ongoing pandemic.
Genomic analysis of SARS-CoV-2 indicates that the virus accumulates two mutations a month, and recent variants have been found to drastically increase infectivity, according to the labs. The 501.V2 mutation originating in South Africa "has been shown to reduce antibody recognition and could therefore affect the efficacy of the licensed vaccines," they said.
While the newly released inoculations focus on SARS-CoV-2, the recent mutations and other developments make the work toward creating a universal vaccine even more important, according to the labs.
"A broad-spectrum vaccine is a necessary next step to protect against continued mutations of SARS-CoV-2 as well as strains that jump from other host to humans or human strains that become more virulent and pose a pandemic threat," they said.
This story contains 534 words.
Stories older than 90 days are available only to subscribing members. Please help sustain quality local journalism by becoming a subscribing member today.
If you are already a subscriber, please log in so you can continue to enjoy unlimited access to stories and archives. Subscriptions start at $5 per month and may be cancelled at any time.